Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07926997
PHASE4

Pharmacokinetics of Oral Zoliflodacin 3 g in Healthy Lactating Women

Sponsor: Global Antibiotics Research and Development Partnership

View on ClinicalTrials.gov

Summary

This is a single-arm clinical trial to evaluate the PK profile in breast milk and plasma after a single oral dose of zoliflodacin in healthy lactating women. Eligible participants who have been actively breastfeeding or expressing milk for at least 4 weeks postpartum will receive a single dose of zoliflodacin administered as an oral suspension with food. Breast milk and plasma samples will be collected at predefined time points for up to 48 hours after dosing to characterize zoliflodacin concentrations and estimate drug exposure in breast milk and maternal plasma. Participants will temporarily discontinue breastfeeding from study check-in until 72 hours after dosing to avoid infant exposure to zoliflodacin. Breast milk will be expressed using an electronic breast pump and collected according to the study schedule. Participants will be admitted to the clinical research unit the day before dosing and discharged after completion of the 48-hour PK sampling period. A follow-up visit will be conducted approximately 7 days after dosing to assess safety and tolerability. A lactation consultant will be available throughout the study period and for up to 30 days after dosing, as needed.

Official title: An Open-label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of Zoliflodacin 3 g in Milk and Plasma in Healthy Lactating Women

Key Details

Gender

FEMALE

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2026-12

Completion Date

2027-08

Last Updated

2026-11-09

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Zoliflodacin

Oral suspension of Zoliflodacin 3g

Locations (1)

TrialMed

Las Vegas, Nevada, United States